Next Pharma Inc. |

Novel Blood and Tissue Tests for Cancer
Diagnosis, Cancer Imaging, and Cancer Vaccine Treatment.

World Cancer Day: Feb 4th ?
Speak up, stand up and take action together.

Next Pharma Inc. (NPI) is a biotechnology company focusing on developing and commercializing product s for the early detection, diagnosis and monitoring the recurrence of cancer and Viral Diseases. Next Pharma has developed a blood ELISA test, using a well-known cancer bio-marker named Aspartyl (Asparaginyl) beta-Hydroxylase (AABH), an enzyme which is over expressed in cancer cells and is the foundation of our breakthrough blood and tissue test technology.

Next Pharma’s novel products are: a blood test that can measure the blood level of Aspartyl (Asparaginyl) β-Hydroxylase (AABH) and an IHC tissue test to detect cancer cells in tissue biopsies. These two products make the foundation of our breakthrough diagnostic technology. Next Pharma Inc., is in a strong position to manufacture, commercialize and market its AABH Blood Test and Tissue Test in late 2024.

Next Pharma’s Mission

Next Pharma’s mission is to discover, develop and commercialize innovative diagnostic products for COVID-19 and Cancer management. Our current product development focus is on novel proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in Oncology, Virology and Vaccine Therapy.

Home

About Us

Technology

COVID-19 and Cancer Tests

Our Team

Publications

Photo Gallery

Contact Us

© 2016 Next Pharma Inc. All Rights Reserved.

Safe Harbor Statement:

Statements in this website that are not strictly historical are “forward-looking” and involve some degree of risk and uncertainty. These include, but are not limited to, statements related to Next Pharma’s technology and product candidates (including Next Pharma’s ability to identify, develop and commercialize new products and product candidates, either independently or with collaboration partners, and Next Pharma’s timetable for doing so), lines of business, markets (including market size and Next Pharma’s ability to identify, develop and commercialize products to address those markets), operations (including Next Pharma’s ability to successfully negotiate and enter intocollaboration partnerships), capabilities, commercialization activities, customer adoption rates, industry conditions, future financial performance, and near-term and long-term growth and prospects. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Next Pharma’s strategic focus, technologies and products (including Next Pharma’s ability to identify, develop and commercialize new products, either independently or with collaboration partners, and market demand for these product and product candidates), dependence on Next Pharma’s discovery.protection and enforcement of its innovations and proprietary rights, the commercial prospects of the industries in which Next Pharma operates and sells products, Next Pharma’s dependence on manufacturing and/or license agreements, its ability to achieve milestones under existing and future collaboration agreements, the ability of Next Pharma’s and its partners to commercialize its products (including by obtaining any required regulatory approvals) using Next Pharma’s technologies, the timing for launching any commercial products and projects, the ability of Next Pharma’s and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Next Pharma to enter into and/or maintain collaboration and joint venture agreements and licenses on a timely basis or at all. These forward-looking statements speak only as of the date hereof, and Next Pharma expressly disclaims any intent or obligation to update these forward-looking statements.

✖ Close the Content Dock